A carregar...
Health care resource utilization before and after natalizumab initiation among patients with multiple sclerosis in Germany
BACKGROUND: Multiple sclerosis (MS), a progressive neurodegenerative disease, greatly impacts the quality of life and economic status of people affected by this disease. In Germany, the total annual cost of MS is estimated at €40,000 per person with MS. Natalizumab has shown to slow MS disease progr...
Na minha lista:
| Publicado no: | Clinicoecon Outcomes Res |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5293187/ https://ncbi.nlm.nih.gov/pubmed/28203098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEOR.S117962 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|